🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. NKTR-102

    Nektar Therapeutics UK Limited

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  2. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  3. NKTR-214

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab completed

    1 trial

  4. NKTR-255 at 1.5 µg/kg

    Nektar Therapeutics UK Limited

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  5. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  6. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  7. NX-5948

    Nurix Therapeutics

    B-cell Lymphoma

    phase 3 small molecule active

    2 trials

  8. Nab-paclitaxel 80 mg/m^2

    CORCEPT THERAPEUTICS INC

    Ovarian Neoplasm

    phase 3 small molecule active

    1 trial

  9. Nalbuphine ER Tablets

    Trevi Therapeutics

    Prurigo Nodularis

    phase 3 small molecule completed

    1 trial

  10. Natriumklorid Braun 9 mg/ml spädningsvätska för parenteral användning, COLECALCIFEROL , GRAZAX 75 000 SQ-T frystorkad sublingual tablett, Alutard SQ Timotej, 10 000 SQ-E/ml, injektionsvätska, suspension

    The George Institute

    Allergisk Rinit

    phase 3 small molecule active

    1 trial

  11. Neugranin

    Teva Pharma GmbH

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  12. Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    4 trials

  13. New thickened formula

    United Therapeutics Europe Ltd

    Gastroesophageal Reflux

    phase 3 other completed

    1 trial

  14. Newnorm

    Maze Therapeutics

    Human Normal Immunoglobulin

    phase 3 small molecule active

    1 trial

  15. Niclosamide

    United Therapeutics Europe Ltd

    Covid19

    phase 3 small molecule completed

    1 trial

  16. Nicotine patch

    Jasper Therapeutics

    Nicotine Dependence

    phase 3 small molecule active

    1 trial

  17. Nicotinomide

    United Therapeutics Europe Ltd

    Glaucoma, Open-Angle

    phase 3 small molecule active

    1 trial

  18. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  19. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial

  20. Normal Saline

    The First People's Hospital of Lianyungang

    Postoperative Sleep Disturbance

    phase 3 small molecule active

    1 trial

  21. Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection

    Amgen

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  22. NurOwn® (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab completed

    2 trials

  23. Nutritional supplements

    United Therapeutics Europe Ltd

    Low Birth Weight

    phase 3 small molecule completed

    1 trial

  24. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics Inc

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources